Features
The Features section includes articles on topics, events, people, and initiatives of interest to the oncology community.
Oct 27, 2021
While there has been progress made in treatments for breast cancers overall, advances specific to invasive lobular carcinoma (ILC) have not kept pace. The Lobular Breast Cancer Alliance (LBCA) is working to change the conversation.
Oct 15, 2021
The internship program aims to increase diversity in the oncology workforce by introducing medical students from populations underrepresented in medicine to oncology concepts and careers.
Sep 01, 2021
Nearly 20 years since receiving a Conquer Cancer Young Investigator Award and Career Development Award, Dr. Yael P. Mossé is launching a new study to unmask how the MYCN culprit causes certain diseases to develop resistance to existing cancer drugs.
Aug 31, 2021
2021 Hologic, Inc Endowed Women Who Conquer Cancer (WWCC) Mentorship Award recipient, Dr. Jennifer A. Ligibel, understands that mentoring is critical in developing the next generation of scientists.
Jul 28, 2021
ASCO’s recent virtual roundtable brought together nationally recognized oncology leaders to examine challenges and solutions to ensuring equitable access to precision medicine for all individuals with cancer.
Jul 15, 2021
Dr. Lori J. Pierce addresses audience questions submitted during the ASCO and Friends of Cancer Research virtual event held on April 9, 2021.
Jul 09, 2021
Dr. Vokes is dedicating his tenure as 2021-2022 ASCO president to expanding ASCO’s global reach and advancing lessons learned from the COVID-19 pandemic to improve cancer care for all patients.
Jul 08, 2021
Dr. Michael A. Thompson addresses audience questions submitted during the ASCO and Friends of Cancer Research virtual event held on April 9, 2021.
Jul 07, 2021
Inaugural Conquer Cancer/Gateway YIA recipient Dr. Connie Lee Batlevi and recent grantee Dr. Laura Agresta discuss how their grants helped shape their careers and research work.
Jun 16, 2021
The latest research supports the use of adjuvant olaparib in patients with high-risk early-stage HER2-negative breast cancer and germline BRCA mutations.